The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients

Purpose The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN dia...

Full description

Saved in:
Bibliographic Details
Published inSupportive care in cancer Vol. 31; no. 7; p. 386
Main Authors Hines, Robert B., Schoborg, Christopher, Sumner, Timothy, Zhu, Xiang, Elgin, Elizabeth A., Zhang, Shunpu
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2023
Springer
Springer Nature B.V
Subjects
Aged
Anticonvulsants
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - adverse effects
Cancer
Cancer patients
Care and treatment
Chemotherapy
Colorectal cancer
Colorectal Neoplasms - drug therapy
Epidemiology
Homeopathy
Humans
Materia medica and therapeutics
Medicare
Medicine
Medicine & Public Health
Medicine, Preventive
Nursing
Nursing Research
Oncology
Oncology, Experimental
Organoplatinum Compounds - adverse effects
Oxaliplatin - adverse effects
Pain Medicine
Peripheral Nervous System Diseases - chemically induced
Peripheral Nervous System Diseases - epidemiology
Peripheral Nervous System Diseases - prevention & control
Peripheral neuropathy
Preventive health services
Rehabilitation Medicine
Retrospective Studies
Side effects
Sociodemographics
Therapeutics
United States
United States
Chemotherapy
Neuropathy
Epidemiology
Treatment-related side effects
Colorectal cancer
Online AccessGet full text
ISSN0941-4355
1433-7339
1433-7339
DOI10.1007/s00520-023-07850-z

Cover

Abstract Purpose The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis. Methods Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation. Results There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75–84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate. Conclusion Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
AbstractList Purpose The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis. Methods Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, [greater than or equal to] 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation. Results There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75-84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate. Conclusion Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis.PURPOSEThe purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis.Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation.METHODSData were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation.There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75-84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate.RESULTSThere were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75-84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate.Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.CONCLUSIONAdditional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis. Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation. There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75-84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate. Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis. Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, [greater than or equal to] 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation. There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75-84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate. Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
PurposeThe purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis.MethodsData were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation.ResultsThere were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75–84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate.ConclusionAdditional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
Purpose The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis. Methods Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation. Results There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75–84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate. Conclusion Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.
ArticleNumber 386
Audience Academic
Author Zhu, Xiang
Hines, Robert B.
Sumner, Timothy
Elgin, Elizabeth A.
Zhang, Shunpu
Schoborg, Christopher
AuthorAffiliation 2 Department of Statistics & Data Science, University of Central Florida College of Sciences, Orlando, FL, USA
4 Department of Medical Education, University of Central Florida College of Medicine, Orlando, FL, USA
3 Office of Research, University of Central Florida College of Medicine, Orlando, FL, USA
1 Department of Population Health Sciences, University of Central Florida College of Medicine, 6900 Lake Nona Blvd., Orlando, FL 328270, USA
AuthorAffiliation_xml – name: 3 Office of Research, University of Central Florida College of Medicine, Orlando, FL, USA
– name: 1 Department of Population Health Sciences, University of Central Florida College of Medicine, 6900 Lake Nona Blvd., Orlando, FL 328270, USA
– name: 2 Department of Statistics & Data Science, University of Central Florida College of Sciences, Orlando, FL, USA
– name: 4 Department of Medical Education, University of Central Florida College of Medicine, Orlando, FL, USA
Author_xml – sequence: 1
  givenname: Robert B.
  orcidid: 0000-0001-7139-3102
  surname: Hines
  fullname: Hines, Robert B.
  email: robert.hines@ucf.edu
  organization: Department of Population Health Sciences, University of Central Florida College of Medicine
– sequence: 2
  givenname: Christopher
  surname: Schoborg
  fullname: Schoborg, Christopher
  organization: Department of Statistics & Data Science, University of Central Florida College of Sciences
– sequence: 3
  givenname: Timothy
  surname: Sumner
  fullname: Sumner, Timothy
  organization: Department of Statistics & Data Science, University of Central Florida College of Sciences
– sequence: 4
  givenname: Xiang
  surname: Zhu
  fullname: Zhu, Xiang
  organization: Department of Population Health Sciences, University of Central Florida College of Medicine, Office of Research, University of Central Florida College of Medicine
– sequence: 5
  givenname: Elizabeth A.
  surname: Elgin
  fullname: Elgin, Elizabeth A.
  organization: Department of Population Health Sciences, University of Central Florida College of Medicine, Department of Medical Education, University of Central Florida College of Medicine
– sequence: 6
  givenname: Shunpu
  surname: Zhang
  fullname: Zhang, Shunpu
  organization: Department of Statistics & Data Science, University of Central Florida College of Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37294347$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNURC_wAiyQJTYsmnJix7msUFVxkyqxKWvL45xMXHnsYGemnb4P78lJp7S0QpUXkX2-_z8-8X-Y7fngMcveFnBSANQfE4DkkAMXOdSNhPzmRXZQlELktRDtXnYAbVnkpZByPztM6RKgqGvJX2X7ouZtKcr6IPt9MSDTKQVj9WSDZwucrhA9m09Ch6uwjHocrDlmxllvjXbHTPuOjWFCP1nt3JaNETfzZoNsGpB4i4ld2Wlg4Vo7Ozqy9rn13dogKTHaccYc87iOYdTTsGXWMxNciGgmKhjtDUZGJUvG6XX2stcu4Zu771H288vni7Nv-fmPr9_PTs9zI0s-5V1Xatl3plyIqsZK9FwUfQEFdLxpeqGrjreCI7SAoOtWQiXAyKbq20a3vC7EUfZp5zuuFyvsDPWma6ox2pWOWxW0VY8r3g5qGTaqgKoBqGaHD3cOMfxaY5rUyiaDzmmPYZ0Ub3hZNbIqK0LfP0Evwzp6mm-mJE0ELX-gltqhsr4P1NjMpuqUHrNsaglA1Ml_KFr0gtZQbHpL548E7_6d9H7Ev8kggO8AE0NKEft7pAA1x0_t4qcofuo2fuqGRM0TkbHTba7oOtY9LxU7aaI-fonx4W88o_oD9U3ysQ
CitedBy_id crossref_primary_10_1093_aje_kwae067
crossref_primary_10_3390_cancers16244244
Cites_doi 10.3988/jcn.2018.14.1.81
10.1200/JCO.2008.20.6771
10.1155/2011/201593
10.1016/j.bbmt.2019.02.018
10.1007/s00520-013-1766-y
10.3389/fphar.2017.00086
10.1007/s00520-014-2408-8
10.1097/CAD.0b013e32832a2dc1
10.1200/JCO.2013.54.0914
10.1200/JCO.2008.19.3425
10.1002/cncr.27732
10.2105/AJPH.2013.301572
10.1200/JOP.2013.001288
10.1016/j.ejon.2019.03.002
10.1212/01.wnl.0000249344.99671.d4
10.1016/j.expneurol.2011.02.019
10.1016/j.clcc.2016.02.009
10.3389/fphar.2017.00344
10.1016/S0895-4356(00)00256-0
10.1007/s00520-012-1667-5
10.1007/s00520-019-05063-x
10.1097/MD.0000000000009125
10.1158/0008-5472.CAN-14-2060
10.1186/s40364-016-0066-3
10.1093/annonc/mdh095
10.4103/jcrt.JCRT_971_16
10.1016/j.tox.2021.152882
10.1007/s00520-013-1905-5
10.1634/theoncologist.2010-0248
10.1159/000362668
10.1007/s00520-015-3063-4
10.1111/bph.15091
10.1007/s00520-014-2255-7
10.1097/COC.0b013e318246b50d
10.3390/molecules26123577
10.1056/NEJMoa032709
10.1186/1744-8069-7-8
10.1186/s12974-019-1581-6
10.1016/j.jphs.2022.01.006
10.1016/j.tox.2011.10.019
10.1159/000094376
10.1200/JCO.2018.36.15_suppl.e18707
10.3390/ijms22010367
10.1097/MLR.0b013e31815cecc3
10.1177/23743735211034028
10.1080/0284186X.2016.1197420
10.1200/JCO.2014.58.8533
10.1089/jpm.2005.8.1118
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
COPYRIGHT 2023 Springer
Copyright_xml – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
– notice: COPYRIGHT 2023 Springer
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
0-V
3V.
7RV
7X7
7XB
88E
88J
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
ALSLI
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HEHIP
K9.
KB0
M0S
M1P
M2R
M2S
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
POGQB
PPXIY
PQEST
PQQKQ
PQUKI
PRQQA
Q9U
7X8
5PM
DOI 10.1007/s00520-023-07850-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Social Sciences Premium Collection
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Social Science Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
Social Science Premium Collection
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Sociology Collection (OCUL)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Social Science Database
Sociology Database (OCUL)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest Sociology & Social Sciences Collection
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest One Social Sciences
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Social Science Journals (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Sociology & Social Sciences Collection
ProQuest Pharma Collection
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Sociology Collection
ProQuest Central (New)
ProQuest Sociology
ProQuest Medical Library (Alumni)
Social Science Premium Collection
ProQuest One Social Sciences
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Sociology Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Social Science Journals
ProQuest Medical Library
ProQuest Social Sciences Premium Collection
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE

ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Nursing
EISSN 1433-7339
EndPage 386
ExternalDocumentID PMC10680061
A752487500
37294347
10_1007_s00520_023_07850_z
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: National Institutes of Health
  grantid: 1 R03 CA241788-01A1; 1 R03 CA241788-01A1
  funderid: http://dx.doi.org/10.13039/100000002
– fundername: NCI NIH HHS
  grantid: R03 CA241788
– fundername: NIH HHS
  grantid: 1 R03 CA241788-01A1
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
0-V
04C
06C
06D
0R~
0VY
123
1N0
1SB
2.D
203
28-
29Q
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3V.
4.4
406
408
409
40D
40E
53G
5QI
5VS
67Z
6NX
6PF
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADOJX
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALSLI
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARALO
ARMRJ
ASOEW
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
ECF
ECT
EIHBH
EIOEI
EJD
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HEHIP
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IHE
IHR
IJ-
IKXTQ
IMOTQ
INH
INR
ITC
ITM
IWAJR
IXC
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
J5H
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M2R
M2S
M4Y
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZMTXR
ZOVNA
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
AEIIB
PMFND
7XB
8FK
ABRTQ
K9.
PJZUB
PKEHL
POGQB
PPXIY
PQEST
PQUKI
PRQQA
Q9U
7X8
5PM
ID FETCH-LOGICAL-c542t-dd4a5fdc4b367e63f231f1010d288f3a6d2932e090e0a7950630c586f98a92713
IEDL.DBID U2A
ISSN 0941-4355
1433-7339
IngestDate Thu Aug 21 18:36:11 EDT 2025
Mon Jul 21 09:53:49 EDT 2025
Sat Jul 26 02:22:53 EDT 2025
Tue Jun 17 22:09:27 EDT 2025
Tue Jun 10 21:06:50 EDT 2025
Mon May 05 07:04:50 EDT 2025
Tue Jul 01 04:26:04 EDT 2025
Thu Apr 24 23:09:12 EDT 2025
Fri Feb 21 02:42:06 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Chemotherapy
Neuropathy
Epidemiology
Treatment-related side effects
Colorectal cancer
Language English
License 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c542t-dd4a5fdc4b367e63f231f1010d288f3a6d2932e090e0a7950630c586f98a92713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Author contribution Robert B. Hines: conceptualization, funding acquisition, methodology, formal analysis, and writing.
Xiang Zhu: data curation, formal analysis, and writing.
Elizabeth A. Elgin: clinical knowledge and writing.
Shunpu Zhang: methodology, study design, and writing.
Christopher Schoborg: data curation, formal analysis, and writing.
Timothy Sumner: data curation, formal analysis, and writing.
ORCID 0000-0001-7139-3102
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/10680061
PMID 37294347
PQID 2825542092
PQPubID 326297
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10680061
proquest_miscellaneous_2824685646
proquest_journals_2825542092
gale_infotracmisc_A752487500
gale_infotracacademiconefile_A752487500
pubmed_primary_37294347
crossref_primary_10_1007_s00520_023_07850_z
crossref_citationtrail_10_1007_s00520_023_07850_z
springer_journals_10_1007_s00520_023_07850_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Supportive care in cancer
PublicationTitleAbbrev Support Care Cancer
PublicationTitleAlternate Support Care Cancer
PublicationYear 2023
Publisher Springer Berlin Heidelberg
Springer
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer
– name: Springer Nature B.V
References Chu, Lee, Lee, Geng, Wang, Cleeland (CR18) 2015; 23
Park, Park, Kim, Yoon, Lee (CR32) 2010; 23
Cheng, Huo, Wang, Cai, Sun, Lu, Yang, Hu, Wang, Cao (CR39) 2017; 8
Izgu, Metin, Karadas, Ozdemir, Cetin, Demirci (CR27) 2019; 40
Andre, Boni, Mounedji-Boudiaf, Navarro, Tabernero, Hickish, Topham, Zaninelli, Clingan, Bridgewater, Tabah-Fisch, de Gramont (CR1) 2004; 350
Argyriou, Chroni, Polychronopoulos, Iconomou, Koutras, Makatsoris, Gerolymos, Gourzis, Assimakopoulos, Kalofonos (CR35) 2006; 67
Banach, Zygulska, Krzemieniecki (CR46) 2018; 14
Raphael, Fischer, Fung, Austin, Anderson, Booth, Singh (CR26) 2017; 16
Pietrangeli, Leandri, Terzoli, Jandolo, Garufi (CR45) 2006; 56
CR36
Corbacioglu, Jabbour, Mohty (CR48) 2019; 25
CR33
CR30
Alejandro, Behrendt, Chen, Openshaw, Shibata (CR19) 2013; 36
Parikh-Patel, Morris, Kizer (CR54) 2017; 96
Gewandter, Kleckner, Marshall, Brown, Curtis, Bautista, Dworkin, Kleckner, Kolb, Mohile, Mustian (CR22) 2020; 28
Hsu, Huang, Lee, Chu, Lin, Lu, Beaton, Jane (CR51) 2019; 28
Vincenzi, Frezza, Schiavon, Spoto, Silvestris, Addeo, Catalano, Graziano, Santini, Tonini (CR52) 2013; 21
Pachman, Qin, Seisler, Smith, Beutler, Ta, Lafky, Wagner-Johnston, Ruddy, Dakhil, Staff, Grothey, Loprinzi (CR44) 2015; 33
Majithia, Temkin, Ruddy, Beutler, Hershman, Loprinzi (CR17) 2016; 24
Tsubota, Fukuda, Hayashi, Miyazaki, Ueda, Yamashita, Koike, Sekiguchi, Wake, Wakatsuki, Ujiie, Araki, Nishibori, Kawabata (CR37) 2019; 16
Kim, Kim, Kim, Woo, Baek, Kim, Chung, Kim (CR20) 2018; 14
Gewandter, Fan, Magnuson, Mustian, Peppone, Heckler, Hopkins, Tejani, Morrow, Mohile (CR15) 2013; 21
Kokotis, Schmelz, Kostouros, Karandreas, Dimopoulos (CR14) 2016; 15
Mihara, Egashira, Sada, Kawashiri, Ushio, Yano, Ikesue, Oishi (CR31) 2011; 7
de Carvalho, Kosturakis, Eng, Wendelschafer-Crabb, Kennedy, Simone, Wang, Cleeland, Dougherty (CR47) 2014; 74
Ghabowen, Bhandari (CR53) 2021; 8
Tofthagen, Donovan, Morgan, Shibata, Yeh (CR16) 2013; 21
Milla, Airoldi, Weber, Drescher, Jaehde, Cattel (CR42) 2009; 20
Rubbia-Brandt, Audard, Sartoretti, Roth, Brezault, Le Charpentier, Dousset, Morel, Soubrane, Chaussade, Mentha, Terris (CR49) 2004; 15
Park, Lin, Krishnan, Goldstein, Friedlander, Kiernan (CR7) 2011; 16
Hershman, Lacchetti, Dworkin, Lavoie Smith, Bleeker, Cavaletti, Chauhan, Gavin, Lavino, Lustberg, Paice, Schneider, Smith, Smith, Terstriep, Wagner-Johnston, Bak, Loprinzi (CR13) 2014; 32
Klabunde, Potosky, Legler, Warren (CR29) 2000; 53
Boyette-Davis, Dougherty (CR12) 2011; 229
Hines, Markossian, Johnson, Dong, Bayakly (CR28) 2014; 104
Ross, Goller, Hardy, Riley, Broadley, A’Hern, Williams (CR34) 2005; 8
Mandelblatt, Huang, Makgoeng, Luta, Song, Tallarico, Roh, Munneke, Houlston, McGuckin, Cai, Clarke Hillyer, Hershman, Neugut, Isaacs, Kushi (CR25) 2015; 11
Andre, Boni, Navarro, Tabernero, Hickish, Topham, Bonetti, Clingan, Bridgewater, Rivera, de Gramont (CR2) 2009; 27
Liu, Zhu, Han, Liu, Ma, Yu (CR41) 2013; 2013
Zhu, Ren, Liu, Zhang (CR50) 2021; 460
Park, Goldstein, Lin, Krishnan, Friedlander, Kiernan (CR8) 2009; 27
Mols, Beijers, Vreugdenhil, van de Poll-Franse (CR6) 2014; 22
Altaf, Lund Brixen, Kristensen, Nielsen (CR10) 2014; 87
Argyriou, Cavaletti, Briani, Velasco, Bruna, Campagnolo, Alberti, Bergamo, Cortinovis, Cazzaniga, Santos, Papadimitriou, Kalofonos (CR11) 2013; 119
Weickhardt, Wells, Messersmith (CR5) 2011; 2011
Jaggi, Singh (CR3) 2012; 291
CR23
Kerckhove, Collin, Conde, Chaleteix, Pezet, Balayssac (CR9) 2017; 8
Esfahani, Somi, Ayromlou, Nikanfar, Jafarabadi, Sadat, Ghoreishi (CR40) 2016; 4
Miyamoto, Domoto, Sekiguchi, Kamaguchi, Nishimura, Matsuno, Tsubota, Fujitani, Hatanaka, Koizumi, Wang, Nishibori, Kawabata (CR43) 2022; 148
CR21
Stefansson, Nygren (CR4) 2016; 55
Lamont, Herndon, Weeks, Henderson, Lilenbaum, Schilsky, Christakis (CR24) 2008; 46
Tsujita, Tsubota, Sekiguchi, Kawabata (CR38) 2021; 178
A Esfahani (7850_CR40) 2016; 4
JS Mandelblatt (7850_CR25) 2015; 11
P Kokotis (7850_CR14) 2016; 15
AA Argyriou (7850_CR35) 2006; 67
DL Hershman (7850_CR13) 2014; 32
SB Park (7850_CR7) 2011; 16
J Boyette-Davis (7850_CR12) 2011; 229
P Milla (7850_CR42) 2009; 20
AS Jaggi (7850_CR3) 2012; 291
C Tofthagen (7850_CR16) 2013; 21
A Parikh-Patel (7850_CR54) 2017; 96
SH Kim (7850_CR20) 2018; 14
N Izgu (7850_CR27) 2019; 40
JS Gewandter (7850_CR22) 2020; 28
IK Ghabowen (7850_CR53) 2021; 8
B Vincenzi (7850_CR52) 2013; 21
R Tsujita (7850_CR38) 2021; 178
R Altaf (7850_CR10) 2014; 87
X Cheng (7850_CR39) 2017; 8
CN Klabunde (7850_CR29) 2000; 53
T Miyamoto (7850_CR43) 2022; 148
JR Ross (7850_CR34) 2005; 8
R Hines (7850_CR28) 2014; 104
BM de Carvalho (7850_CR47) 2014; 74
SY Hsu (7850_CR51) 2019; 28
F Mols (7850_CR6) 2014; 22
AA Argyriou (7850_CR11) 2013; 119
N Kerckhove (7850_CR9) 2017; 8
C Zhu (7850_CR50) 2021; 460
7850_CR30
7850_CR33
T Andre (7850_CR1) 2004; 350
M Tsubota (7850_CR37) 2019; 16
DR Pachman (7850_CR44) 2015; 33
7850_CR36
T Andre (7850_CR2) 2009; 27
Y Mihara (7850_CR31) 2011; 7
L Rubbia-Brandt (7850_CR49) 2004; 15
SB Park (7850_CR8) 2009; 27
N Majithia (7850_CR17) 2016; 24
SH Chu (7850_CR18) 2015; 23
JS Gewandter (7850_CR15) 2013; 21
M Stefansson (7850_CR4) 2016; 55
MJ Raphael (7850_CR26) 2017; 16
7850_CR23
7850_CR21
A Pietrangeli (7850_CR45) 2006; 56
Y Liu (7850_CR41) 2013; 2013
A Weickhardt (7850_CR5) 2011; 2011
EB Lamont (7850_CR24) 2008; 46
BY Park (7850_CR32) 2010; 23
LM Alejandro (7850_CR19) 2013; 36
M Banach (7850_CR46) 2018; 14
S Corbacioglu (7850_CR48) 2019; 25
References_xml – volume: 32
  start-page: 1941
  year: 2014
  end-page: 1967
  ident: CR13
  article-title: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline
  publication-title: J Clin Oncol
– volume: 14
  start-page: 81
  year: 2018
  end-page: 89
  ident: CR20
  article-title: A prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy
  publication-title: J Clin Neurol
– volume: 53
  start-page: 1258
  year: 2000
  end-page: 1267
  ident: CR29
  article-title: Development of a comorbidity index using physician claims data
  publication-title: J Clin Epidemiol
– volume: 67
  start-page: 2253
  year: 2006
  end-page: 2255
  ident: CR35
  article-title: Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy
  publication-title: Neurology
– volume: 36
  start-page: 331
  year: 2013
  end-page: 337
  ident: CR19
  article-title: Predicting acute and persistent neuropathy associated with oxaliplatin
  publication-title: Am J Clin Oncol
– volume: 2011
  start-page: 201593
  year: 2011
  ident: CR5
  article-title: Oxaliplatin-induced neuropathy in colorectal cancer
  publication-title: J Oncol
– volume: 8
  start-page: 1118
  year: 2005
  end-page: 1126
  ident: CR34
  article-title: Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study
  publication-title: J Palliat Med
– volume: 96
  start-page: e9125
  year: 2017
  ident: CR54
  article-title: Disparities in quality of cancer care: the role of health insurance and population demographics
  publication-title: Medicine (Baltimore)
– volume: 4
  start-page: 13
  year: 2016
  ident: CR40
  article-title: The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial
  publication-title: Biomark Res
– volume: 21
  start-page: 2059
  year: 2013
  end-page: 2066
  ident: CR15
  article-title: Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study
  publication-title: Support Care Cancer
– volume: 15
  start-page: 460
  year: 2004
  end-page: 466
  ident: CR49
  article-title: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer
  publication-title: Ann Oncol
– volume: 291
  start-page: 1
  year: 2012
  end-page: 9
  ident: CR3
  article-title: Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
  publication-title: Toxicology
– volume: 460
  start-page: 152882
  year: 2021
  ident: CR50
  article-title: Oxaliplatin-induced hepatic sinusoidal obstruction syndrome
  publication-title: Toxicology
– volume: 229
  start-page: 353
  year: 2011
  end-page: 357
  ident: CR12
  article-title: Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline
  publication-title: Exp Neurol
– volume: 21
  start-page: 3307
  year: 2013
  end-page: 3313
  ident: CR16
  article-title: Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors
  publication-title: Support Care Cancer
– ident: CR21
– volume: 21
  start-page: 1313
  year: 2013
  end-page: 1319
  ident: CR52
  article-title: Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
  publication-title: Support Care Cancer
– volume: 8
  start-page: 23743735211034028
  year: 2021
  ident: CR53
  article-title: Concordance and patient-centered care in Medicaid enrollees’ care experience with providers
  publication-title: J Patient Exp
– volume: 28
  start-page: 2553
  year: 2020
  end-page: 2562
  ident: CR22
  article-title: Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data
  publication-title: Support Care Cancer
– volume: 28
  start-page: e12976
  year: 2019
  ident: CR51
  article-title: Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer
  publication-title: European J Cancer Care
– volume: 22
  start-page: 2261
  year: 2014
  end-page: 2269
  ident: CR6
  article-title: Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review
  publication-title: Support Care Cancer
– volume: 8
  start-page: 344
  year: 2017
  ident: CR39
  article-title: Herbal medicine AC591 prevents oxaliplatin-induced peripheral neuropathy in animal model and cancer patients
  publication-title: Front Pharmacol
– volume: 11
  start-page: e1
  year: 2015
  end-page: 8
  ident: CR25
  article-title: Preliminary development and evaluation of an algorithm to identify breast cancer chemotherapy toxicities using electronic medical records and administrative data
  publication-title: J Oncol Pract
– volume: 148
  start-page: 315
  year: 2022
  end-page: 325
  ident: CR43
  article-title: Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Eeidence from clinical and preclinical studies
  publication-title: J Pharmacol Sci
– volume: 16
  start-page: 199
  year: 2019
  ident: CR37
  article-title: Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants
  publication-title: J Neuroinflammation
– ident: CR36
– volume: 23
  start-page: 513
  year: 2015
  end-page: 524
  ident: CR18
  article-title: Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review
  publication-title: Support Care Cancer
– volume: 40
  start-page: 36
  year: 2019
  end-page: 43
  ident: CR27
  article-title: Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: an assessor-blinded randomized controlled trial
  publication-title: Eur J Oncol Nurs
– volume: 104
  start-page: e63
  year: 2014
  end-page: 71
  ident: CR28
  article-title: Geographic residency status and census tract socioeconomic status as determinants of colorectal cancer outcomes
  publication-title: Am J Public Health
– volume: 15
  start-page: e133
  year: 2016
  end-page: 140
  ident: CR14
  article-title: Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study
  publication-title: Clin Colorectal Cancer
– volume: 2013
  start-page: 541217
  year: 2013
  ident: CR41
  article-title: Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial
  publication-title: Evid Based Complement Alternat Med
– volume: 55
  start-page: 1227
  year: 2016
  end-page: 1235
  ident: CR4
  article-title: Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life
  publication-title: Acta Oncol
– ident: CR30
– ident: CR33
– volume: 14
  start-page: 1010
  year: 2018
  end-page: 1013
  ident: CR46
  article-title: Oxaliplatin treatment and peripheral nerve damage in cancer patients: a Polish cohort study
  publication-title: J Cancer Res Ther
– volume: 46
  start-page: 303
  year: 2008
  end-page: 308
  ident: CR24
  article-title: Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants
  publication-title: Med Care
– volume: 16
  start-page: 708
  year: 2011
  end-page: 716
  ident: CR7
  article-title: Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility
  publication-title: Oncologist
– volume: 27
  start-page: 3109
  year: 2009
  end-page: 3116
  ident: CR2
  article-title: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
  publication-title: J Clin Oncol
– volume: 23
  start-page: 179
  year: 2010
  end-page: 185
  ident: CR32
  article-title: Antinociceptive effect of memantine and morphine on vincristine-induced peripheral neuropathy in rats Korean
  publication-title: J Pain
– ident: CR23
– volume: 8
  start-page: 86
  year: 2017
  ident: CR9
  article-title: Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review
  publication-title: Front Pharmacol
– volume: 20
  start-page: 396
  year: 2009
  end-page: 402
  ident: CR42
  article-title: Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics Pt-DNA adduct formation, and neurotoxicity
  publication-title: Anti-Cancer Drugs
– volume: 7
  start-page: 8
  year: 2011
  ident: CR31
  article-title: Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats
  publication-title: Mol Pain
– volume: 56
  start-page: 13
  year: 2006
  end-page: 16
  ident: CR45
  article-title: Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up
  publication-title: Eur Neurol
– volume: 74
  start-page: 5955
  year: 2014
  end-page: 5962
  ident: CR47
  article-title: A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy
  publication-title: Cancer Res
– volume: 25
  start-page: 1271
  year: 2019
  end-page: 1280
  ident: CR48
  article-title: Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome
  publication-title: Biol Blood Marrow Tr
– volume: 27
  start-page: 1243
  year: 2009
  end-page: 1249
  ident: CR8
  article-title: Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity
  publication-title: J Clin Oncol
– volume: 87
  start-page: 167
  year: 2014
  end-page: 172
  ident: CR10
  article-title: Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer
  publication-title: Oncology
– volume: 33
  start-page: 3416
  year: 2015
  end-page: 3422
  ident: CR44
  article-title: Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance)
  publication-title: J Clin Oncol
– volume: 350
  start-page: 2343
  year: 2004
  end-page: 2351
  ident: CR1
  article-title: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
  publication-title: N Engl J Med
– volume: 178
  start-page: 798
  year: 2021
  end-page: 812
  ident: CR38
  article-title: Role of high-mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain
  publication-title: Br J Pharmacol
– volume: 119
  start-page: 438
  year: 2013
  end-page: 444
  ident: CR11
  article-title: Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer
  publication-title: Cancer
– volume: 24
  start-page: 1439
  year: 2016
  end-page: 1447
  ident: CR17
  article-title: National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons
  publication-title: Support Care Cancer
– volume: 16
  start-page: e391
  issue: 397–404
  year: 2017
  ident: CR26
  article-title: Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer
  publication-title: Clin Colorectal Cancer
– volume: 14
  start-page: 81
  year: 2018
  ident: 7850_CR20
  publication-title: J Clin Neurol
  doi: 10.3988/jcn.2018.14.1.81
– volume: 27
  start-page: 3109
  year: 2009
  ident: 7850_CR2
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.6771
– ident: 7850_CR30
– volume: 2011
  start-page: 201593
  year: 2011
  ident: 7850_CR5
  publication-title: J Oncol
  doi: 10.1155/2011/201593
– volume: 23
  start-page: 179
  year: 2010
  ident: 7850_CR32
  publication-title: J Pain
– volume: 25
  start-page: 1271
  year: 2019
  ident: 7850_CR48
  publication-title: Biol Blood Marrow Tr
  doi: 10.1016/j.bbmt.2019.02.018
– volume: 21
  start-page: 2059
  year: 2013
  ident: 7850_CR15
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-013-1766-y
– ident: 7850_CR21
– volume: 8
  start-page: 86
  year: 2017
  ident: 7850_CR9
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2017.00086
– volume: 23
  start-page: 513
  year: 2015
  ident: 7850_CR18
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-014-2408-8
– volume: 20
  start-page: 396
  year: 2009
  ident: 7850_CR42
  publication-title: Anti-Cancer Drugs
  doi: 10.1097/CAD.0b013e32832a2dc1
– volume: 32
  start-page: 1941
  year: 2014
  ident: 7850_CR13
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.54.0914
– volume: 27
  start-page: 1243
  year: 2009
  ident: 7850_CR8
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.3425
– volume: 119
  start-page: 438
  year: 2013
  ident: 7850_CR11
  publication-title: Cancer
  doi: 10.1002/cncr.27732
– volume: 104
  start-page: e63
  year: 2014
  ident: 7850_CR28
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.2013.301572
– volume: 11
  start-page: e1
  year: 2015
  ident: 7850_CR25
  publication-title: J Oncol Pract
  doi: 10.1200/JOP.2013.001288
– volume: 40
  start-page: 36
  year: 2019
  ident: 7850_CR27
  publication-title: Eur J Oncol Nurs
  doi: 10.1016/j.ejon.2019.03.002
– volume: 67
  start-page: 2253
  year: 2006
  ident: 7850_CR35
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000249344.99671.d4
– volume: 229
  start-page: 353
  year: 2011
  ident: 7850_CR12
  publication-title: Exp Neurol
  doi: 10.1016/j.expneurol.2011.02.019
– volume: 15
  start-page: e133
  year: 2016
  ident: 7850_CR14
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2016.02.009
– volume: 8
  start-page: 344
  year: 2017
  ident: 7850_CR39
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2017.00344
– volume: 53
  start-page: 1258
  year: 2000
  ident: 7850_CR29
  publication-title: J Clin Epidemiol
  doi: 10.1016/S0895-4356(00)00256-0
– volume: 21
  start-page: 1313
  year: 2013
  ident: 7850_CR52
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-012-1667-5
– volume: 28
  start-page: 2553
  year: 2020
  ident: 7850_CR22
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-019-05063-x
– volume: 96
  start-page: e9125
  year: 2017
  ident: 7850_CR54
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000009125
– volume: 74
  start-page: 5955
  year: 2014
  ident: 7850_CR47
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-2060
– volume: 4
  start-page: 13
  year: 2016
  ident: 7850_CR40
  publication-title: Biomark Res
  doi: 10.1186/s40364-016-0066-3
– volume: 15
  start-page: 460
  year: 2004
  ident: 7850_CR49
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdh095
– volume: 14
  start-page: 1010
  year: 2018
  ident: 7850_CR46
  publication-title: J Cancer Res Ther
  doi: 10.4103/jcrt.JCRT_971_16
– volume: 460
  start-page: 152882
  year: 2021
  ident: 7850_CR50
  publication-title: Toxicology
  doi: 10.1016/j.tox.2021.152882
– volume: 21
  start-page: 3307
  year: 2013
  ident: 7850_CR16
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-013-1905-5
– volume: 16
  start-page: 708
  year: 2011
  ident: 7850_CR7
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2010-0248
– volume: 87
  start-page: 167
  year: 2014
  ident: 7850_CR10
  publication-title: Oncology
  doi: 10.1159/000362668
– volume: 24
  start-page: 1439
  year: 2016
  ident: 7850_CR17
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-015-3063-4
– volume: 16
  start-page: e391
  issue: 397–404
  year: 2017
  ident: 7850_CR26
  publication-title: Clin Colorectal Cancer
– volume: 178
  start-page: 798
  year: 2021
  ident: 7850_CR38
  publication-title: Br J Pharmacol
  doi: 10.1111/bph.15091
– volume: 22
  start-page: 2261
  year: 2014
  ident: 7850_CR6
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-014-2255-7
– volume: 36
  start-page: 331
  year: 2013
  ident: 7850_CR19
  publication-title: Am J Clin Oncol
  doi: 10.1097/COC.0b013e318246b50d
– ident: 7850_CR33
  doi: 10.3390/molecules26123577
– volume: 2013
  start-page: 541217
  year: 2013
  ident: 7850_CR41
  publication-title: Evid Based Complement Alternat Med
– volume: 350
  start-page: 2343
  year: 2004
  ident: 7850_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa032709
– volume: 7
  start-page: 8
  year: 2011
  ident: 7850_CR31
  publication-title: Mol Pain
  doi: 10.1186/1744-8069-7-8
– volume: 16
  start-page: 199
  year: 2019
  ident: 7850_CR37
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-019-1581-6
– volume: 148
  start-page: 315
  year: 2022
  ident: 7850_CR43
  publication-title: J Pharmacol Sci
  doi: 10.1016/j.jphs.2022.01.006
– volume: 291
  start-page: 1
  year: 2012
  ident: 7850_CR3
  publication-title: Toxicology
  doi: 10.1016/j.tox.2011.10.019
– volume: 56
  start-page: 13
  year: 2006
  ident: 7850_CR45
  publication-title: Eur Neurol
  doi: 10.1159/000094376
– ident: 7850_CR23
  doi: 10.1200/JCO.2018.36.15_suppl.e18707
– ident: 7850_CR36
  doi: 10.3390/ijms22010367
– volume: 28
  start-page: e12976
  year: 2019
  ident: 7850_CR51
  publication-title: European J Cancer Care
– volume: 46
  start-page: 303
  year: 2008
  ident: 7850_CR24
  publication-title: Med Care
  doi: 10.1097/MLR.0b013e31815cecc3
– volume: 8
  start-page: 237437352110340
  year: 2021
  ident: 7850_CR53
  publication-title: J Patient Exp
  doi: 10.1177/23743735211034028
– volume: 55
  start-page: 1227
  year: 2016
  ident: 7850_CR4
  publication-title: Acta Oncol
  doi: 10.1080/0284186X.2016.1197420
– volume: 33
  start-page: 3416
  year: 2015
  ident: 7850_CR44
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.58.8533
– volume: 8
  start-page: 1118
  year: 2005
  ident: 7850_CR34
  publication-title: J Palliat Med
  doi: 10.1089/jpm.2005.8.1118
SSID ssj0017752
Score 2.3896058
Snippet Purpose The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced...
The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced...
Purpose The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced...
PurposeThe purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 386
SubjectTerms Aged
Anticonvulsants
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - adverse effects
Cancer
Cancer patients
Care and treatment
Chemotherapy
Colorectal cancer
Colorectal Neoplasms - drug therapy
Epidemiology
Homeopathy
Humans
Materia medica and therapeutics
Medicare
Medicine
Medicine & Public Health
Medicine, Preventive
Nursing
Nursing Research
Oncology
Oncology, Experimental
Organoplatinum Compounds - adverse effects
Oxaliplatin - adverse effects
Pain Medicine
Peripheral Nervous System Diseases - chemically induced
Peripheral Nervous System Diseases - epidemiology
Peripheral Nervous System Diseases - prevention & control
Peripheral neuropathy
Preventive health services
Rehabilitation Medicine
Retrospective Studies
Side effects
Sociodemographics
Therapeutics
United States
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgiftvzlAiCD24wTdO0fZJDPA5BnzzYt5LmAxfWtne7J979P_d_OpOmXbvgvTZJSTu_ZGaSmd8Q8g5cgKrIVMmk9ZpJl-esEVIxX2ohi8pbb0OU73d1eia_LvNlPHDbxLDKcU8MG7XtDJ6Rf8Qcy1wKXolP_TnDqlF4uxpLaNwl95C6DEO6iuXkcKVFESrugAcDfhIo1pg0E1LnQgAIA43FQEnmnF3PFNP-9vyPftqPndy7QA166eQReRgNSno8IOAxuePaJ-T-t3hl_pTcABCo3gmBxsgsik86634NnNUrs6BjluSC6tbSvttiJJFer69oH4mefjs6JGyBf03xCJd2f8CQ7zGgrmXg3gNQYCSgOrAVrGmgy8Sqx1d01VJkyMYdFhoMou2CRlrXzTNydvLlx-dTFmszMANS2DJrpc69NbLJVOFU5sFO9LC8uRVl6TOtLNgRwvGKO66LKkdqL5OXylelrgR4xs_JQdu17iWh2vPSgl1otJaySY12IBF4fdoAVETjE5KOgqlNJC7H-hnreqJcDsKsQZh1EGZ9nZAP05h-oO24tfd7lHeNaxrebHRMTYD5ITtWfQw4QseO84QczXrCWjTz5hExddwLNvUOuQl5OzXjSIxva113GfpIVeZKqoS8GAA2zRsvVmUmi4SUM-hNHZAhfN7Srn4GpvAUK6uAxZaQxYjS3bz-_z8Ob_-MV-SBGBYO4-kROdheXLrXYJptmzdh_f0FgpI5CQ
  priority: 102
  providerName: ProQuest
Title The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients
URI https://link.springer.com/article/10.1007/s00520-023-07850-z
https://www.ncbi.nlm.nih.gov/pubmed/37294347
https://www.proquest.com/docview/2825542092
https://www.proquest.com/docview/2824685646
https://pubmed.ncbi.nlm.nih.gov/PMC10680061
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dixMxEB-8OxRfRM-v1bNEEHywgf3Ifj220nooFhEL9WnJbhKuUHfLtXfc3f_j_-lMNrtniwo-LWwmIez8kpnZzPwC8AZDgDyNkowLZSQXOo55GYqEm0yGIs2NMspm-c6S07n4uIgXrihs02W7d0eSdqfui91sygZHG8PRrMU-vzmAo5hid0TxPBz1Zwdpau_ZwbgFoyM0p65U5s9j7Jij_U35N6u0nzG5d2xqrdH0ITxwbiQbtXp_BHd0fQz3PruD8mO46_4CPIafCAQmb5XAXGYWozeN0j9azuplNWRdleSQyVqxdbOlTCK5Wl2ztSN6utSsLdjC-JrRL1zWXKEjv6aEuppjeI9AwZ6IastWsGKWLpNuPb5my5oRQzbtsNhQEdrOmaN13TyB-XTy7f0pd3cz8CoW4ZYrJWRsVCXKKEl1Ehn0Ew0ub1-FWWYimSj0I0Lt5772ZZrHRO1VxVli8kzmIUbGT-Gwbmr9HJg0fqbQL6ykFKIMKqlRNzh8UCJUwtJ4EHQqKipHXE73Z6yKnnLZqrVAtRZWrcWNB-_6PuuWtuOf0m9J8wWtaRy5kq40AedH7FjFCBFFgZ3ve3CyI4lrsdpt7rBTuL1gU1B1MH4zPw89eN03U0_Kb6t1c2FlRJLFiUg8eNZCrZ83HayKSKQeZDsg7AWIIXy3pV6eWabwgG5WQY_Ng2GH19t5_f17vPg_8ZdwP2yXFPeDEzjcnl_oV-iqbcsBHKSLdABHo-l4PKPnh--fJvgcT2Zfvg7suv0FEBc_AQ
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG8CBYwE4sBaZBPndUCoQKstbVcItVJvwYltsdKSLN0tsP0_XPmNzDhOll2J3nqNH3Iyn2c88cw3AM_RBciSME65UEZyoaOIF4GIuUllIJLMKKNslO8oHh6LjyfRyQb8aXNhKKyy1YlWUau6pH_krynHMhKBnwVvp985VY2i29W2hEYDi329-Iku2-zN3geU74sg2N05ej_krqoAL3H8nCslZGRUKYowTnQcGjzhGASmr4I0NaGMFVrAQPuZr32ZZBGRUpVRGpsslVmAPh3OewU2RYiuTA823-2MPn3u7i2SxNb4QZ8JPTM05S5Nxybr2ZATjjaSo1mOfH6-YgrXDcI_FnE9WnPtytZawt2bcMMdYdl2g7lbsKGr23D10F3S34HfCD0ml2JnLhaM0ZNa6W8NS_a47LM2L7PPZKXYtJ5T7JKcTBZs6qilfmjWpIihR8_opzGrf6HrMKUQvoqPK4XQxJG4jyw_woRZgk6qs7xg44oRJzfpdGwoCd-nzBHJzu7C8aXI7R70qrrSD4BJ46cKT6KllEIUg1JqlAhOPygQnEFhPBi0gslLR5VOFTsmeUfybIWZozBzK8z83INX3ZhpQxRyYe-XJO-ctAjOXEqXDIHrIz6ufBtxRK6k73uwtdITd3-52twiJnfaZ5Yv94oHz7pmGkkRdZWuz2wfEadRLGIP7jcA69ZNV7kiFIkH6Qr0ug7ESb7aUo2_Wm7yAdVywTOiB_0Wpct1_f97PLz4NZ7CteHR4UF-sDfafwTXg2YTcX-wBb356Zl-jAfDefHE7UYGXy5bAfwFxOF1ig
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIlVcEO-6FFgkEAeyqr1evw4IVZSopVBxoFJuZr0PESm1Q5MC6f_hT_DrmFmvHRKJ3nrNPuR4vpnZ8c58Q8gLCAGKLE5zJrSVTJgkYRUXKbO55CIrrLbaZfmepIen4sMoGW2QP10tDKZVdjbRGWrdKPxGvoc1longYcH3rE-L-HwwfDv9zrCDFN60du00Wogcm8VPCN9mb44OQNYvOR--__LukPkOA0zBXnOmtZCJ1UpUcZqZNLZw2rEA0lDzPLexTDV4Q27CIjShzIoECapUkqe2yGXBIb6DfW-Qm1mcRKhj2agP9qIsc91-IHqCGA2cui_YcWV7LvmEgbdk4KCTkF2uOMV11_CPb1zP21y7vHU-cXiH3PaHWbrfou8u2TD1PbL1yV_X3ye_AYRULgFAfVYYxV8abc5avuyxGtCuQnNAZa3ptJljFpOcTBZ06kmmfhjaFotBbE_x8zFtfkEQMcVkvpqNaw0ghZWgUY4pYUIdVSd2XF7QcU2RnRutOwwoRPo59ZSyswfk9Fqk9pBs1k1ttgmVNsw1nEmVlEJUkZIGJALbRxXAlFc2IFEnmFJ50nTs3TEpe7pnJ8wShFk6YZaXAXndr5m2lCFXzn6F8i7RnsDOSvqyCHg-ZOYq9wFHGFSGYUB2V2aCHVCrwx1iSm-HZuVSawLyvB_GlZhbV5vmws0RaZ6kIg3IoxZg_XPjpa6IRRaQfAV6_QRkJ18dqcffHEt5hF1d4LQYkEGH0uVz_f997Fz9N56RLVD78uPRyfFjcou3OsTCaJdszs8vzBM4Ic6rp04VKfl63br_F_FGeFo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+association+between+sociodemographic%2C+clinical%2C+and+potentially+preventive+therapies+with+oxaliplatin-induced+peripheral+neuropathy+in+colorectal+cancer+patients&rft.jtitle=Supportive+care+in+cancer&rft.au=Hines%2C+Robert+B.&rft.au=Schoborg%2C+Christopher&rft.au=Sumner%2C+Timothy&rft.au=Zhu%2C+Xiang&rft.date=2023-07-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0941-4355&rft.eissn=1433-7339&rft.volume=31&rft.issue=7&rft_id=info:doi/10.1007%2Fs00520-023-07850-z&rft.externalDocID=10_1007_s00520_023_07850_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0941-4355&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0941-4355&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0941-4355&client=summon